GO
Loading...

Enter multiple symbols separated by commas

Pharmaceuticals

More

  • President Bush renewed his veto threat today as the House of Representatives passed legislation that would require the government to negotiate drug prices for Medicare patients.

  • Retail Analysis: Good Growth Making A Soft Landing? Friday, 12 Jan 2007 | 10:25 AM ET

    Even though the lights are packed away and the tree has been stripped bare, Santa brought one last gift to investors today. New data shows holiday shopping was more robust than Wall Street had expected. The U.S. Commerce Department reported retail sales rose 0.9% in December, that’s the strongest increase in 5 months.

  • Mylan CEO: We're World Leader in Generic Drugs Tuesday, 9 Jan 2007 | 3:04 PM ET

    More than $18 billion in pharmaceutical drugs are scheduled to go off-patent this year, and consequently medication makers are getting lots of attention from Wall Street. One company expected to benefit from patent expiration is generic drug manufacturer Mylan Labs. CNBC's Mike Huckman caught up with CEO Robert Coury at the JPMorgan Healthcare Conference in San Francisco.

  • Amylin Feeling Pressure From Competition Tuesday, 9 Jan 2007 | 11:34 AM ET
    Amylin

    Amylin Pharmaceuticals has felt the pressure of late since Merck released a diabetes drug to rival its own Byetta. And there’s no relief in sight with Novartis not far behind in getting approval for its Galvus treatment. CNBC’s Mike Huckman spoke with Amylin CEO Ginger Graham about how the competition is affecting the company.

  • The U.S. Supreme Court sided with MedImmune and reinstated the company's lawsuit challenging the validity of a key Genentech patent.

  • Celgene CEO Barer: EPS Down For Q4 Tuesday, 9 Jan 2007 | 10:32 AM ET

    As we've said--CNBC pharmaceuticals reporter Mike Huckman is at the 25th Annual JPMorgan Healthcare Conference in San Francisco this week. This morning on “Squawk on the Street” he got a chance to talk to Celgene Chairman and CEO Sol Barer. Barer’s company is up 365% over the past three years and has a cancer-fighting drug he says has “multibillion-dollar potential.” 

  • huckman_Bio_Photos_US_120.jpg

    You’ll find some of the most influential figures in modern healthcare in San Francisco today, gathered together for the 25th Annual J.P. Morgan Healthcare Conference.  This year, 6500 people are attending, including CNBC’s Mike Huckman who is sifting through volumes of data. In a  "First on CNBC,"  Huckman spoke with James Sabry, M.D./Ph. D., the CEO of Cytokinetics. 

  • CNBC'S Domm: A Real "News Feast" Next Week Friday, 5 Jan 2007 | 9:43 PM ET

    Financial markets will have plenty of news to feast on in the coming week although the markets generated enough headlines on their own in the first days of January with just a few big stories to chew on. The second week of January is quite busy. We're looking forward to some of the most important and newsy industry conferences of the year, plus the start of earnings season, an important Fed speech, and some fresh economic data.

  • Hope Remains for Genentech Cancer Drug Friday, 5 Jan 2007 | 12:22 PM ET

    An ovarian cancer drug under development by Genentech that many investors had written off showed promise in a midstage trial, even though the trial may not have met its main goal.

  • CNBC’s Schacknow: It’s All About the Video Thursday, 4 Jan 2007 | 1:51 PM ET

    If you’ve been extremely bored and somehow stumbled across my bio on the cnbc.com site, you’ll note that I have an extensive background in radio. Radio, as many have noted, has no pictures and is beautiful in its simplicity. TV, on the other hand, is nothing without pictures.

  • BioCryst Pharmaceuticals has won a $102.6 million government contract for advanced development of its influenza antiviral drug, peramivir.

  • Schering-Plough, OraSure to Develop Hepatitis C Test Thursday, 4 Jan 2007 | 12:19 PM ET

    Schering-Plough and OraSure Technologies said they have entered a two-year deal to jointly develop and market a rapid oral test for the detection of hepatitis C virus antibodies.

  • Eli Lilly said it entered into settlement agreements with 14 groups involved in Zyprexa liability suits and will take a fourth-quarter charge of up to $500 million related to the litigation.

  • California Here I Come ... Again Wednesday, 3 Jan 2007 | 3:22 PM ET

    Just got back from a glorious trip to Pasadena where the outcome for my Trojans (apologies to any Michigan Wolverine fans reading this) was much better this year than last. And in a few days, we'll be heading back West to San Francisco to cover the JPMorgan Healthcare Conference which starts next Monday. This year, more than 300 companies will be presenting to nearly 7,000 attendees. That makes it the biggest healthcare investment conference...

  • Exelixis, Genentech Strike Drug Development Pact Wednesday, 3 Jan 2007 | 10:24 AM ET

    Drug developer Exelixis Wednesday it agreed to develop cancer drug candidate XL518 with biotech drug maker Genentech.

  • Siemens Completes Takeover of Bayer Unit Wednesday, 3 Jan 2007 | 3:40 AM ET

    Siemens AG said Wednesday it has completed its euro4.2 billion (US$5.57 billion) takeover of the diagnostics division of Bayer AG's health care business.

  • 'Dow Dogs' Offer Double Path to Profit? Friday, 29 Dec 2006 | 11:04 AM ET

    Almost every analyst has an angle on how to beat the market, and investors pay big money for trading tips that promise guaranteed profits. But here on CNBC we give that advice away for free. John Prestbo, editor of Dow Jones Indexes, shared his “Dogs of the Dow” strategy on “Morning Call” today. It returned 32% in 2006.

  • Sanofi-Aventis said it has won in an appeal by Canadian generic drugmaker Apotex which is prohibited from selling cheaper copies of Sanofi's bloodthinner Plavix in Canada.

  • Glaxo Breast Cancer Drug Shows Promise, Study Says Thursday, 28 Dec 2006 | 7:34 AM ET

    A study being published in a major medical journal confirms the promise of a breast cancer drug from GlaxoSmithKline that's awaiting the approval of the Food and Drug Administration, CNBC's Mike Huckman reports.

  • CNBC's Huckman: The Hazards Of Biotech Investing Wednesday, 27 Dec 2006 | 2:26 PM ET
    huckman_Bio_Photos_US_120.jpg

    Shares of Telik are plunging today, after its leading cancer drug failed late stage trials. CNBC'S Pharmaceuticals Reporter, Mike Huckman had more on the hazards of investing in biotech on "Power Lunch." Huckman says that in biotech it can be boom or bust if you're going to invest in the volatile sector and that there should be an assumed risk of caveat emptor--buyer beware.